Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1990 Oct;82(1):57–62. doi: 10.1111/j.1365-2249.1990.tb05403.x

Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors.

C Ross 1, M B Hansen 1, T Schyberg 1, K Berg 1
PMCID: PMC1535177  PMID: 2119920

Abstract

Recently, naturally occurring antibodies to IFN-alpha were discovered in a few systemic lupus erythematosus (SLE) and cancer patients; however, in most patients monitored for anti-IFN antibodies before treatment, no antibodies were found. In an attempt to explain the 'IFN-blocking effect' that we observed in all serum samples we investigated 200 sera from healthy blood donors. We isolated the globulin fraction, and used rabbit anti-human IgG and IgM columns, protein A columns and T-gel affinity chromatography to isolate human IgG and IgM. All sample fractions were tested in a biological IFN neutralization assay by means of a sensitive MTT-assay. We found that normal human serum contained autoantibodies to crude human leucocyte IFN, native human fibroblast IFN, recombinant human leucocyte IFN-alpha 2b and recombinant human IFN-gamma, and that these naturally occurring antibodies were biologically active immunoglobulins of IgG and IgM type. These anti-IFN antibodies were also present in purified human normal immunoglobulin pools. We conclude that all humans have naturally occurring anti-interferon antibodies in their serum, and it is a tempting theory that human cytokines and lymphokines are, at least partly, regulated by immunoglobulins.

Full text

PDF
57

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cantell K., Hirvonen S., Mogensen K. E., Pyhälä L. Human leukocyte interferon: production, purification, stability, and animal experiments. In Vitro Monogr. 1974;(3):35–38. [PubMed] [Google Scholar]
  2. De Maeyer-Guignard J., Cachard-Thomas A., De Maeyer E. Naturally occurring anti-interferon antibodies in Lou/c rats. J Immunol. 1984 Aug;133(2):775–778. [PubMed] [Google Scholar]
  3. Figlin R. A., deKernion J. B., Mukamel E., Palleroni A. V., Itri L. M., Sarna G. P. Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation. J Clin Oncol. 1988 Oct;6(10):1604–1610. doi: 10.1200/JCO.1988.6.10.1604. [DOI] [PubMed] [Google Scholar]
  4. Hansen M. B., Nielsen S. E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods. 1989 May 12;119(2):203–210. doi: 10.1016/0022-1759(89)90397-9. [DOI] [PubMed] [Google Scholar]
  5. Hansen M. B., Ross C., Berg K. A sensitive antiviral neutralization bioassay for measuring antibodies to interferons. J Immunol Methods. 1990 Mar 9;127(2):241–248. doi: 10.1016/0022-1759(90)90074-6. [DOI] [PubMed] [Google Scholar]
  6. Hutchens T. W., Porath J. Thiophilic adsorption of immunoglobulins--analysis of conditions optimal for selective immobilization and purification. Anal Biochem. 1986 Nov 15;159(1):217–226. doi: 10.1016/0003-2697(86)90331-3. [DOI] [PubMed] [Google Scholar]
  7. Mogensen K. E., Daubas P., Gresser I., Sereni D., Varet B. Patient with circulating antibodies to alpha-interferon. Lancet. 1981 Nov 28;2(8257):1227–1228. doi: 10.1016/s0140-6736(81)91460-4. [DOI] [PubMed] [Google Scholar]
  8. Porath J., Maisano F., Belew M. Thiophilic adsorption--a new method for protein fractionation. FEBS Lett. 1985 Jun 17;185(2):306–310. doi: 10.1016/0014-5793(85)80928-5. [DOI] [PubMed] [Google Scholar]
  9. Porath J. Salt-promoted adsorption: recent developments. J Chromatogr. 1986 Apr 11;376:331–341. doi: 10.1016/s0378-4347(00)80850-6. [DOI] [PubMed] [Google Scholar]
  10. Steis R. G., Smith J. W., 2nd, Urba W. J., Clark J. W., Itri L. M., Evans L. M., Schoenberger C., Longo D. L. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med. 1988 Jun 2;318(22):1409–1413. doi: 10.1056/NEJM198806023182201. [DOI] [PubMed] [Google Scholar]
  11. Svenson M., Poulsen L. K., Fomsgaard A., Bendtzen K. IgG autoantibodies against interleukin 1 alpha in sera of normal individuals. Scand J Immunol. 1989 Apr;29(4):489–492. doi: 10.1111/j.1365-3083.1989.tb01149.x. [DOI] [PubMed] [Google Scholar]
  12. Towbin H., Gordon J. Immunoblotting and dot immunobinding--current status and outlook. J Immunol Methods. 1984 Sep 4;72(2):313–340. doi: 10.1016/0022-1759(84)90001-2. [DOI] [PubMed] [Google Scholar]
  13. Trown P. W., Kramer M. J., Dennin R. A., Jr, Connell E. V., Palleroni A. V., Quesada J., Gutterman J. U. Antibodies to human leucocyte interferons in cancer patients. Lancet. 1983 Jan 15;1(8316):81–84. doi: 10.1016/s0140-6736(83)91737-3. [DOI] [PubMed] [Google Scholar]
  14. Vallbracht A., Treuner J., Manncke K. H., Niethammer D. Autoantibodies against human beta interferon following treatment with interferon. J Interferon Res. 1982;2(1):107–110. doi: 10.1089/jir.1982.2.107. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES